latest news releases from the newsroom
ALCO Stores, Inc.
Duckwall-ALCO Stores Will Report Operating Results for Second Quarter Fiscal 2008 Ending July 29, 2007 on Thursday, September 6, 2007
ABILENE, Kan., Aug. 28, 2007 (PRIME NEWSWIRE) -- Duckwall-ALCO Stores, Inc. (Nasdaq:DUCK) today announced that it will report second quarter fiscal 2008 operating results on Thursday, September 6, 2007 after the market closes. The Company will host an investor conference call the following morning at 10:00 a.m. central daylight time to discuss operating results in greater detail.
Teresis Media Management, Inc.
Teresis Online Delivers 'Immeasurable Efficiency' to Norsemen Television Productions
SANTA ANA, Calif., Aug. 28, 2007 (PRIME NEWSWIRE) -- Norsemen Television Productions, LLC is one of a variety of entertainment production companies enjoying the many benefits of using Teresis Online(tm) to improve its pre and post production processes. Developed by Teresis Media Management, Inc., Teresis Online(tm) is the industry's first and only completely Internet-based video production asset management solution. Its unique software-as-a-service model helps Norsemen lower costs, reduce time to market and deliver high quality productions all at the same time.
JetBlue Airways Corporation
JetBlue Airways Customers Countdown to Fall Savings
NEW YORK, Aug. 28, 2007 (PRIME NEWSWIRE) -- JetBlue Airways Corporation (Nasdaq:JBLU) today launches a three-day Countdown Sale, with special low fares available on flights to most JetBlue destinations. Fares as low as $49(a) are available between New York/JFK and Burlington, VT; Buffalo, Rochester and Syracuse, NY; Pittsburgh, PA; Portland, ME; and Richmond, VA; as well as between Boston and Buffalo, NY. Fares as low as $59(a) are available between Washington, DC/Dulles and Florida. Fares as low as $139(a) are available between New York and California.
Cannasat Therapeutics Inc.
Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2007
TORONTO, Aug. 28, 2007 (PRIME NEWSWIRE) -- Cannasat Therapeutics Inc. (TSX-V:CTH), the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the six months ended June 30, 2007. Cannasat also reports that activities over this period have led to approval from Health Canada to commence its first Phase 1 clinical study with its lead product, CAT 310, for patients with neuropathic pain. The study is expected to be completed in Q4 2007 and represents a major milestone for the Company.